Generic Cancer Drugs: The Hope and Hidden Challenges

How do generics and biosimilars revolutionize cancer treatment? This video explores the affordability vs. quality dilemma in oncology, highlighting how generic drugs like Imatinib, Dasatinib, and Olaparib have slashed treatment costs by up to 80%. Learn about India’s innovative National Cancer Grid and its role in reducing cancer drug prices by 85%, while also uncovering challenges like quality control lapses and generic drug shortages. Join me as I discuss the trade-offs of generics, the impact on global healthcare, and the future of affordable cancer care solutions.

⌚️Timestamps:
00:00 - Introduction
- Overview of generics and biosimilars
00:15 Understanding the Basics
- Difference between generics and biosimilars
- Research evidence and effectiveness
00:38 Cost Impact
- 80% price reduction examples
- Case studies: Dasatinib and Olaparib price changes
01:02 The Indian Healthcare Model
- National Cancer Grid initiative
- Collective purchasing success
01:16 Challenges and Concerns
- Manufacturing and quality control issues
- Regulatory oversight problems
01:35 Future Implications
- Impact on healthcare access
- Supply chain challenges

Click on the link to book an appointment:

WhatsApp (for appointments & queries) – 9346524080

I’m Dr. Madhav Danthala, a Consultant Medical Oncologist, Hemato Oncologist and Bone Marrow Transplant physician at Yashoda Hospitals, Somajiguda, Hyderabad, India. I received a degree in Medical Oncology from prestigious Nizam’s Institute of Medical Sciences, Hyderabad, and a Fellowship in Leukemia/Bone Marrow Transplant from the University of British Columbia, Vancouver, Canada. I’ve worked at Manipal Hospitals, Vijayawada from 2017 to 2022, before moving to Yashoda Hospitals, Somajiguda, Hyderabad, India.